Low-dose naltrexone, a generic drug that costs as little as $29.81 for a month’s supply, is quietly becoming one of the most widely used treatments in long COVID clinics across the United States. Originally approved by the FDA at 50 mg doses to treat opioid and alcohol addiction, naltrexone at much lower doses — typically 1 to 4.5 mg per day — is showing real promise in reducing the brain fog, crushing fatigue, and chronic pain that define long COVID for millions of people. According to reporting by The Sick Times, almost every long COVID clinic in the country is now prescribing it.
For a condition that currently has zero FDA-approved treatments, that level of clinical adoption is remarkable. An estimated 11 percent of Americans who contracted COVID-19 have gone on to develop long COVID, and globally, roughly 43 percent of people who had acute infections experience lingering symptoms. For those patients, and particularly for older adults and people already managing cognitive decline, the persistent neuroinflammation behind long COVID brain fog represents a serious threat to quality of life. This article examines what the research actually shows about low-dose naltrexone, where the evidence is strong, where it falls short, and what patients and caregivers should realistically expect.
Table of Contents
- What Is Low-Dose Naltrexone and Why Is This Cheap Generic Drug Getting Attention for Long COVID?
- What Does the Research Actually Show About LDN for Long COVID?
- The Biological Mechanism — Why LDN May Work on Brain Fog and Neuroinflammation
- How Patients Can Access LDN and What It Actually Costs
- Why Hasn’t the FDA Approved LDN for Long COVID — and What Trials Are Underway?
- LDN and the Overlap With Dementia-Related Cognitive Symptoms
- What Comes Next for LDN and Long COVID Treatment
- Conclusion
- Frequently Asked Questions
What Is Low-Dose Naltrexone and Why Is This Cheap Generic Drug Getting Attention for Long COVID?
Naltrexone is not a new or exotic medication. It has been on the market for decades as a treatment for addiction, and because its patent expired long ago, it is only available in generic form. A 30-day supply of standard 50 mg tablets runs about $29.81 with a GoodRx coupon or roughly $36.99 through SingleCare, compared to $88 to $160 at full retail price. The catch is that long COVID patients need doses far below what commercial tablets provide.
At 1 to 4.5 mg, the drug must be prepared by a compounding pharmacy, which can add out-of-pocket costs that insurance rarely covers. At these low doses, naltrexone behaves differently than it does at addiction-treatment levels. Rather than simply blocking opioid receptors full-time, LDN appears to have anti-inflammatory and immunomodulatory properties. Researchers believe this is what makes it useful against the persistent neuroinflammation that drives brain fog and fatigue in long COVID. For a patient who went from running a household to struggling to remember where they put their keys, the biological mechanism matters less than the practical result — but understanding why it works helps explain why clinicians have embraced it despite the limited formal evidence.
What Does the Research Actually Show About LDN for Long COVID?
The honest answer is that the research is promising but still early. A systematic review published in September 2025 screened 226 studies on LDN for long COVID and found only four observational pre-post studies, conducted in the United States and Ireland, covering a total of 155 patients. No randomized controlled trials — the gold standard for medical evidence — have been completed yet. That is a significant limitation, and patients should understand it clearly before setting expectations.
That said, the studies that do exist are encouraging. A 2024 pilot study of 36 patients treated with 4.5 mg of LDN daily, combined with NAD+ supplementation, showed significant improvement in quality of life scores and a meaningful reduction in fatigue after 12 weeks. The treatment was well tolerated, with minimal side effects. Separately, a retrospective study of 59 patients at a single academic center found that 52 percent were responders after 12 weeks, and those taking LDN had a 5.04 times higher relative hazard of improvement compared to patients receiving physical therapy alone. However, if a patient has only mild symptoms or symptoms unrelated to neuroinflammation, these results may not apply — LDN is not a catch-all, and responder rates suggest nearly half of patients in that study did not see meaningful benefit.
The Biological Mechanism — Why LDN May Work on Brain Fog and Neuroinflammation
One of the more compelling recent developments came from a 2025 study published in Frontiers in Molecular Biosciences, which found that low-dose naltrexone restored the function of TRPM3 ion channels in natural killer cells taken from long COVID patients. This is significant because TRPM3 dysfunction has been linked to the immune dysregulation seen in both long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. The finding provides a concrete biological explanation for what clinicians have been observing anecdotally. For readers of a brain health publication, the neuroinflammation angle deserves particular attention.
Chronic inflammation in the brain is not just a long COVID problem — it is a central feature of Alzheimer’s disease, vascular dementia, and age-related cognitive decline. A patient in their sixties who develops long COVID brain fog may already have been on a trajectory toward mild cognitive impairment. adding persistent neuroinflammation to that baseline can accelerate decline in ways that are difficult to reverse. If LDN can dampen that inflammation safely, it has implications beyond long COVID alone, though researchers are careful to note that such extrapolation remains speculative without dedicated trials.
How Patients Can Access LDN and What It Actually Costs
Getting low-dose naltrexone is straightforward in theory but can be frustrating in practice. Because LDN is an off-label use of a generic drug, most primary care physicians can prescribe it, but many are unfamiliar with it or reluctant to prescribe outside established guidelines. Long COVID specialty clinics are the most reliable source. The prescription itself calls for naltrexone at doses between 1 and 4.5 mg, which a compounding pharmacy then prepares — standard 50 mg tablets cannot simply be split to achieve these doses with any accuracy. The cost comparison is worth understanding.
The base drug is genuinely inexpensive: around $30 for generic tablets with a discount coupon. But compounding pharmacy fees vary widely, from $30 to $90 per month depending on the pharmacy, the dose, and the formulation. Insurance coverage for compounded medications is inconsistent at best. Compare this to other long COVID interventions — months of specialized physical therapy, cognitive rehabilitation programs, or experimental treatments that can run into thousands of dollars — and LDN looks remarkably affordable. The tradeoff is that you are paying out of pocket for a treatment that, while widely used clinically, lacks the large-scale trial data that would force insurers to cover it.
Why Hasn’t the FDA Approved LDN for Long COVID — and What Trials Are Underway?
The gap between clinical adoption and regulatory approval is not unusual in medicine, but it is worth understanding. No pharmaceutical company has a financial incentive to fund the expensive randomized controlled trials that the FDA requires, because naltrexone is a cheap generic with no patent protection. There is no blockbuster drug revenue waiting at the end of that investment. This means the burden falls on academic researchers and government funding, which moves slowly. Multiple clinical trials are currently underway in the United States, Australia, Spain, and Canada testing LDN for long COVID, ME/CFS, and fibromyalgia.
Until those trials report results, the medical community’s position remains cautious: LDN appears safe and may be effective for some patients, but rigorous evidence is still needed. Patients should be wary of anyone — whether a clinician or a website — who presents LDN as a guaranteed cure. It is not. Roughly half the patients in the best available study did not respond, and we do not yet have reliable ways to predict who will benefit and who will not. A February 2026 study also began examining LDN prescribing practices specifically in children and adolescents aged 25 and under across three pediatric long COVID programs, signaling that interest in the drug spans all age groups but that evidence in younger populations is even thinner.
LDN and the Overlap With Dementia-Related Cognitive Symptoms
For caregivers managing a loved one with both cognitive decline and post-COVID symptoms, the overlap can be disorienting. A 74-year-old with early-stage Alzheimer’s who contracts COVID and develops worsening brain fog presents a clinical puzzle — how much of the decline is the underlying disease, and how much is potentially treatable neuroinflammation? Some long COVID clinicians have begun considering LDN for older patients precisely because its side effect profile is mild and the potential upside, even if modest, could preserve months of functional independence. One academic center’s retrospective data showed that responders typically noticed improvement within the first 12 weeks, giving clinicians a relatively quick window to assess whether the drug is helping before committing to long-term use.
What Comes Next for LDN and Long COVID Treatment
The next 12 to 24 months should bring much-needed clarity. With randomized controlled trials running across four countries and mechanistic research identifying specific biological targets like TRPM3 ion channel restoration, the field is moving from anecdote toward evidence. If the RCTs confirm what observational studies have suggested, LDN could become one of the first formally validated treatments for long COVID — and at a price point that makes it accessible to nearly anyone.
For now, patients and caregivers should approach LDN with informed optimism rather than desperation. It is a real drug with a plausible mechanism, widespread clinical use, and a favorable safety profile. It is also a drug without definitive proof of efficacy from large trials. That combination — genuinely promising, not yet proven — is exactly where most medical breakthroughs spend an uncomfortable amount of time before the data catches up to the practice.
Conclusion
Low-dose naltrexone represents something unusual in modern medicine: a cheap, widely available generic drug that clinicians have adopted broadly for long COVID despite the absence of large randomized trials. The existing evidence — including pilot studies showing significant fatigue reduction, retrospective data suggesting responders have five times the likelihood of improvement, and mechanistic research identifying how LDN restores immune cell function — paints a cautiously encouraging picture. For patients dealing with brain fog, fatigue, and pain after COVID-19, particularly older adults for whom cognitive decline carries outsized consequences, LDN offers a low-risk option worth discussing with a physician.
The critical next step is patience paired with advocacy. Patients should ask their doctors about LDN, seek out long COVID clinics that have experience prescribing it, and understand that results typically take around 12 weeks to evaluate. Caregivers managing loved ones with both dementia and post-COVID symptoms should bring up the possibility of neuroinflammation as a treatable contributor to worsening cognition. And everyone involved should keep an eye on the ongoing clinical trials in the U.S., Australia, Spain, and Canada, because their results will determine whether LDN moves from promising off-label treatment to standard of care.
Frequently Asked Questions
What is low-dose naltrexone and how is it different from regular naltrexone?
Naltrexone is FDA-approved at 50 mg to treat opioid and alcohol addiction. Low-dose naltrexone uses the same drug at 1 to 4.5 mg per day, a dose range that produces anti-inflammatory and immunomodulatory effects rather than opioid-blocking effects. At these doses, it must be prepared by a compounding pharmacy because commercial tablets only come in 50 mg.
How much does LDN cost for long COVID treatment?
Generic naltrexone tablets cost as little as $29.81 for 30 tablets with a GoodRx coupon. However, because LDN requires compounding to achieve the low doses needed, patients typically face additional compounding pharmacy fees that can range from $30 to $90 per month. Insurance coverage for compounded medications is inconsistent.
Is LDN FDA-approved for long COVID?
No. There are currently no FDA-approved treatments specifically for long COVID. LDN is prescribed off-label, meaning doctors use their clinical judgment to prescribe it for a condition it was not originally approved to treat. Multiple clinical trials are underway in the U.S., Australia, Spain, and Canada to build the evidence base.
How long does it take for LDN to work on long COVID symptoms?
In the available studies, patients were typically evaluated after 12 weeks of treatment. A retrospective study of 59 patients found that 52 percent were responders at the 12-week mark. Patients who do not see improvement within this timeframe may not be candidates for continued treatment.
Are there side effects of low-dose naltrexone?
In the studies conducted so far, LDN has been well tolerated with minimal side effects. The most commonly reported issues at low doses include vivid dreams, mild headache, and temporary nausea, though these tend to resolve within the first few weeks. The safety profile is one reason clinicians have been comfortable prescribing it broadly.
Can LDN help with dementia-related brain fog or just long COVID brain fog?
Current research on LDN has focused on long COVID and related conditions like ME/CFS and fibromyalgia. While the anti-inflammatory mechanism is theoretically relevant to neuroinflammation in dementia, there are no clinical trials specifically testing LDN for Alzheimer’s or other dementias. Any use in that context would be highly speculative and should only be considered in consultation with a neurologist.
